Insulin Analogues — Potentials for Improving Diabetes Treatment

  • F. B. Hansen
  • I. G. Clausen
  • B. Dath
  • E. B. Jensen
  • B. R. Johansen
  • I. Jonassen
  • F. Junker
  • K. D. Jørgensen
  • G. Meyn
  • J. Petersen
  • P. Balschmidt
Conference paper
Part of the Bayer AG Centenary Symposium book series (BAYER)

Abstract

Despite many years of clinical experimentation with commercially available short-, intermediate-, and long-acting insulin preparations, good metabolic control is still difficult to attain in a large proportion of insulin-dependent diabetics. Two basic problems emerge from the clinical studies: 1. the rate of insulin uptake after sub-cutaneous injection of conventional short-acting preparations is too slow; and 2. the pharmacokinetics of intermediate- and long-acting preparations vary too much.

Keywords

Zinc Crystallization Glycerol Phenol Amide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bradbury AF, Ko AS, Massey DE, Salokangas A, Smyth DG, Sabery GA, Webb FW, Steward GA (1973) The quest for a latent action insulin. Postgrad Med J (Suppl) 49: 945–948Google Scholar
  2. Brake AJ, Merryweather JP, Coit DG, Heberlein UA, Masiarz FR, Mullenbach GT, Urdea MS, Valenzuela P, Barr PJ (1984) B-factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 81: 4642–4646PubMedCrossRefGoogle Scholar
  3. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sørensen AR, Voigt HO (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333: 679–682PubMedCrossRefGoogle Scholar
  4. Fischer WH, Saunders D, Brandenburg D, Wollmer A, Zahn H (1985) A shortened insulin with full in vitro potency. Biol Chem Hoppe-Seyler 366: 521–525PubMedCrossRefGoogle Scholar
  5. Gattner HG (1975) Darstellung und Eigenschaften von Des-Pentapeptid (B26-30)-Rinderinsulin. Hoppe-Seylers Z Physiol Chem 356: 1397–1404PubMedCrossRefGoogle Scholar
  6. Grau U (1985) Insulin-Arg2: A new retard-principle based on a natural proinsulin-derived processing intermediate. Diabetes Res Clin Pract Suppl 1: S204Google Scholar
  7. Krayenbühl C, Rosenberg T (1946) Cryastalline protamine-insulin. Reports Steno Mem Hosp Nordisk Insulinlab 1: 60–73Google Scholar
  8. Kunkel TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 82: 448–492Google Scholar
  9. Markussen J, Hougaard P, Ribel U, Sørensen AR, Sørensen E (1987a) Soluble, prolonged-acting insulin derivatives. I. Degree of protaction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng 1: 205–213Google Scholar
  10. Markussen J, Diers I, Englsgaard A, Hansen MT, Hougaard P, Langkjaer L, Norris K, Ribel U, Sørensen AR, Sørensen E, Voigt HO (1987b) Soluble, prolonged-acting insulin derivatives. II. Degree of protaction and crystallizability of insulins substituted in positions A17, B8, B13, B27. Protein Eng 1: 215–223PubMedCrossRefGoogle Scholar
  11. Sonne O (1985) In vitro biological characterization of iodinated insulin preparations. In: Larner O, Poll SL (eds) Methods in diabetes research, vol I: Laboratory Methods. Wiley, New York, pp 433–451Google Scholar
  12. Zahn H, Naithani VK, Gattner HG, Biillesbach EE, Tharum PM (1981) Protein-Semisynthese mit Hilfe gemischter Anhydride und Enzyme. Naturwissenschaften 68: 56–62PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • F. B. Hansen
  • I. G. Clausen
  • B. Dath
  • E. B. Jensen
  • B. R. Johansen
  • I. Jonassen
  • F. Junker
  • K. D. Jørgensen
  • G. Meyn
  • J. Petersen
  • P. Balschmidt

There are no affiliations available

Personalised recommendations